1Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines. Circulation ,2004, 110:227-239.
2National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel Ⅲ) final report. Circulation, 2002, 106 :3143 -3421.
5Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke : systematic review and meta-analysis. BMJ, 2003,326 : 1423.
6Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet,2002,360:7-22.
7Shepherd J, Blauw GJ, Murphy MB, et al. Pravaststin in elderly individuals at risk of vascular disease ( PROSPER ) : a randomize dcontrolled trial. Lancet ,2002,360 : 1623-1630.
8Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr,1994,48 : 305-325.
9Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomized placebo-controlled trail. Lancet, 2003, 361 :2005-2016.
10Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med, 2004,350:1495-1504.
3Rubins HB, Robins S, Collins D, et al. Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol 1995, 75:1196-1201.
4Sacco RL, Benson RT, Kargman DE, et al. High density lipoprotein cholesterol and ischemic stroke in the elderly, The Northem Manhattan Stroke Study. JAMA, 2001, 285:2729-2735.
5Von Eckardstein A, Asgmann G. Prevention of coronary heart disease by raising high density lipoprotein cholesterol? Curr Opin Lipidol, 2000, 11:627-637.
6Schmity G, Langman T. Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol, 2001, 12:129-140.
7Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease, Four Prospective American Studies. Circulation, 1989, 79:8-15.
8Frick MH, Elo O, Heapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibozil in middle aged man with dyslipidemia, safety of treatment, changes in risk factors, and incidence of CHD. N Eng J Med, 1987, 317:1237-1245.
9Rubins HB, Robins S, Collins D, et al. (Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group) Gemfibrozil for the secondery prevention of coronary heart disease in men with low levels of HDL-C. N Eng J Med, 1999, 341:410-418.
10She MP, Wong ZL. The protective role of high density lipoprotein in atherosclerosis. Exp Gerontol, 1999, 34:539-548.
